Rahmer Peter 4
4 · Relay Therapeutics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Relay Therapeutics (RLAY) Chief Corp Dev Officer Peter Rahmer Sells Shares
What Happened Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), sold 50,000 shares on June 30, 2026 in an open-market/private sale for a weighted average price of $19.09, totaling approximately $954,500. On the same date he acquired 3,056 shares under the company's 2020 Employee Stock Purchase Plan (ESPP) at $6.95 per share for about $21,239. The sale was a disposition (often routine), while the ESPP purchase is a direct buy by the insider.
Key Details
- Transaction date(s): June 30, 2026.
- Sale: 50,000 shares sold at a weighted average price of $19.09 (trade prices ranged $18.66–$19.78); total proceeds ~$954,500.
- Purchase: 3,056 shares acquired under ESPP at $6.95 per share; total cost ~$21,239.
- Shares owned after transaction: the excerpt does not state total beneficial ownership; filing notes holdings include 9,153 shares underlying restricted stock units (RSUs).
- Notable footnotes:
- Sale executed pursuant to a pre-established Rule 10b5-1 trading plan adopted Oct 31, 2025.
- Seller will provide, upon request, a breakdown of the multiple trade prices within the $18.66–$19.78 range.
- ESPP purchase was exempt under Rule 16b-3 and was purchased at 85% of the Jan 2, 2026 closing price (voluntarily reported).
- Filing timeliness: Report filed July 2, 2026 for a June 30 transaction — appears timely.
Context A sale executed under a 10b5-1 plan is generally pre-scheduled and is commonly seen in insider Form 4s; it doesn't necessarily signal a change in insider view. The ESPP purchase is a direct insider buy and is typically viewed as a straightforward acquisition of company shares. This filing is factual disclosure of both a sizable sale and a small ESPP purchase; it does not reveal the insider's motives.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-06-30$19.09/sh−50,000$954,500→ 225,857 total - Award
Common Stock
[F4][F5][F3]2026-06-30$6.95/sh+3,056$21,239→ 228,913 total
Footnotes (5)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $18.66 to $19.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 9,153 shares underlying restricted stock units.
- [F4]The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
- [F5]In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026.